The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.
Fluxion develops cellular analysis tools in the pharmaceutical, biotech and research industries. The company has developed a proprietary microfluidic platform which enables precise cellular manipulation, rapid low-volume compound addition, environmental control and software-based data acquisition.
Bionanotechnology and microfluidics provide the foundations for GeneFluidics' testing platform. The use of bionanotechnology drives high signal to noise ratios (sensitivity), while the incorporation of microfluidics permits operational simplicity.
One of the world's foremost biotechnology companies, the company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing.
A spin off founded to commercialize FDEC FET nano sensor technology invented at Arizona State University.The novel nano sensor technology is capable of exponential capacitive transduction for ultra high sensitivity molecular detection, coupled with exceptional selectivity.
Iris Biotechnologies is dedicated to the development of Nano-Biochip gene expression kits to assist in establishing a solid and reliable foundation for personalized medicine. The company's patented products were developed to overcome the sensitivity, specificity, speed and cost limitations of present state-of-the-art microarray technology.
Keystone Nano has an exclusive license to Penn State patented technology that allows the creation of stable, non-toxic, 5 to 50 nm-composite particles that they call Molecular Dots (MDs). These Molecular Dots can encapsulate drugs and/or fluorescent molecules.
A cell culture/biotech company making strides in enhancing organ preservation and cell culturing at both room temperature and through cryopreservation. The LIFOR® technology is the nanoparticle component of the solution, which carries the oxygen or any type of drug or nutrient that the developers wish to place into the nanoparticle.
Makefield Therapeutics has licensed Intellectual Property covering a novel platform technology from Albert Einstein College of Medicine of Yeshiva University for the generation of powders comprised of hydrogel/glassy matrix (hybrid) nanoparticles that in a first application are delivering controlled and sustained therapeutic levels of gaseous nitric oxide